Paran Goel

Dr. Paran Goel

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2025 in Blood
Verified
Journal Article
Open access
PGParan Goel
Paran Goel
SASajesan Aryal
Sajesan Aryal
AFAlana M. Franceski
Alana M. Franceski
VKValeriya Kuznetsova
Valeriya Kuznetsova
ACAmanda Costa
Amanda Costa
RWRobert Welner
Robert Welner
Acute myeloid leukemia (AML), an aggressive hematological malignancy, is driven by oncogenic mutations in stem and progenitor cells that give rise to AML blasts. Although these mutations are well characterized, their impact on healthy hematopoiesis, those blood cells exposed to AML but not mutated, has not been well characterized. Because the marrow is the major site for granulopoiesis, neutrophils are heavily influenced by AML pathobiology. Indeed, most patients with AML report neutropenia, rendering them susceptible to infections. However, because AML studies use peripheral blood mononuclear cells devoid of neutrophils, the characterization of neutrophil dysfunction remains poorly understood. To investigate AML-exposed neutrophils, a preclinical AML mouse model in which primary leukemic cells were transplanted into nonirradiated neutrophil reporter (Ly6G-tdTomato; Catchup) hosts was used. Neutrophils could not completely mature, suggesting impaired granulopoiesis. Single-cell transcriptomics of AML-exposed neutrophils revealed higher inflammation signatures and expression of CD14, an inflammatory marker. To address the factors contributing to this biology, an ex vivo cytokine screen was performed on marrow neutrophils, and it identified that nuclear factor κB signaling drove CD14 expression. AML-exposed neutrophils displayed widespread chromatin remodeling, and de novo motif discovery predicted increased binding sites for CCAAT enhancer–binding proteins and interferon regulatory factors. Moreover, AML-exposed neutrophils inhibited T-cell proliferation, highlighting their immune-suppressive capability. Finally, a similar biology of immature, inflammatory neutrophils was found in patients with AML, again indicating dysregulated granulopoiesis. Collectively, these data show that AML-associated inflammation alters neutrophil granulopoiesis, impairs neutrophil function, and drives immunosuppression, thereby contributing to patient susceptibility to infection.

13 February 2025 in Blood Advances
Verified
Journal Article
Open access
VKValeriya Kuznetsova
Valeriya Kuznetsova
VKVaidehi Krishnan
Vaidehi Krishnan
ACAmanda Costa
Amanda Costa
XRXi Ren
Xi Ren
TRTiffany D. Ricketts
Tiffany D. Ricketts
RWRobert Welner
Robert Welner
Natural killer (NK) cells play an integral role in immunosurveillance against myeloid malignancies, with their mature phenotype and abundance linked to prolonged treatment-free remission in chronic myeloid leukemia (CML). However, NK cell function is suppressed during the disease, and the orchestrators of this impairment are not fully understood. Using a chimeric BCR::ABL1+ CML mouse model, we characterized the impact of the leukemic microenvironment on NK cell function. We showed that NK cells have reduced counts, immature phenotype, poor cytotoxicity, and altered expression of activating and inhibitory receptors in CML mice, which revert to a steady state upon BCR::ABL1 inhibition. Single-cell RNA sequencing revealed an inflammatory cytokine response in CML-exposed NK cells, highlighted by the tumor necrosis factor α (TNFα)-induced gene signature, upregulation of TNFα receptor 2, and enrichment of suppressor of cytokine signaling family genes such as Cish, the critical NK cell checkpoint. Ex vivo exposure of healthy NK cells to leukemic soluble factors compromised target-specific NK cell degranulation, which was partially rescued by targeting Cish or TNFα. In alignment with these findings, NK cells from healthy donors displayed suppressed cytotoxicity when exposed to plasma from untreated patients with CML, with a partial restoration upon Cish or TNFα inhibition. Furthermore, NK cells from newly diagnosed patients with CML predestined for blast crisis showed an enrichment of the TNFα-induced proinflammatory gene signature identified in CML mice. These results suggest that targeting inflammatory signaling could enhance NK cell-based immunotherapies for CML.

1 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
RSReegan L Sturgeon
Reegan L Sturgeon
PGParan Goel
Paran Goel
CMCaitlin Molczyk
Caitlin Molczyk
RBRidhi Bhola
Ridhi Bhola
PGPaul M. Grandgenett
Paul M. Grandgenett
Rakesh SinghRakesh Singh
Rakesh Singh
Background: Tumor-promoting inflammation and immune evasion are hallmarks of cancer, contributing to the survival and proliferation of tumor cells. Infiltrating leukocytes and pro-inflammatory cytokines released into the tumor microenvironment (TME) often cause this inflammation and immune evasion. Neutrophils are leukocytes that contribute to inflammation and have immunomodulatory functions. They are shown to have pro- or anti-tumorigenic roles contingent on cancer type. Methods: In this study, we examined the role of neutrophil recruitment in pancreatic cancer (PC) progression using patient samples and murine models. Results: We observed enhanced neutrophil infiltration and neutrophil extracellular trap (NET) formation, which were dependent on disease stage and tumor site. Our murine model studies showed that the infiltration of neutrophils and NETs was dependent on disease progression. Moreover, chemokine receptor CXCR2 and its ligands played a crucial role in neutrophil recruitment. The expression of CXCR2 and its ligands was associated with a worse prognosis for patients. Conclusions: Our data demonstrates that gemcitabine therapy enhances neutrophil recruitment and NET formation in PC. In addition, we observed altered neutrophil phenotypes in PC dependent on disease progression, suggesting a context-dependent immunomodulatory role. Together, our data demonstrate that CXCR2-driven neutrophil recruitment increases with PC progression, is enhanced by gemcitabine chemotherapy, promotes an immunosuppressive microenvironment, and is associated with poor patient survival.

12 February 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
NPNestor Prieto-Dominguez
Nestor Prieto-Dominguez
PGParan Goel
Paran Goel
OOOluwagbemiga A. Ojo
Oluwagbemiga A. Ojo
KMKatarina Moretto
Katarina Moretto
AHAlisha Holtzhausen
Alisha Holtzhausen
EUEric Ubil
Eric Ubil
Traditional anticancer therapies induce tumor cell death and subsequent release of damage-associated molecular patterns (DAMPs) that activate the innate inflammatory response. Paradoxically, after treatment, macrophages often adopt a pro–wound healing, rather than proinflammatory, phenotype and contribute to cancer progression. We found that in areas proximal to DAMP release, tumor cells upregulate the expression of Pros1. Tumor-secreted Pros1 binds to the macrophage Mer receptor, consequently limiting responsiveness to DAMPs by preventing Toll-like receptor signal transduction. Pharmacological inhibition of PTP1b signaling downstream of Mer rescued the proinflammatory response, even in the presence of Pros1. Combining protein tyrosine phosphatase (PTP) inhibition with traditional therapeutics, such as chemo- or radiotherapy, rescued the innate immune response to DAMPs, increased immune infiltration, and resulted in a 40% to 90% reduction in tumor growth in multiple treatment-refractory preclinical models. Our findings suggest using PTP1b inhibitors may be a tumor agnostic means of improving the efficacy of some of the most widely used anticancer therapeutic agents.

17 June 2026
Verified
Other
Open access
PDF file
NPNestor Prieto-Dominguez
Nestor Prieto-Dominguez
PGParan Goel
Paran Goel
OOOluwagbemiga A. Ojo
Oluwagbemiga A. Ojo
KMKatarina Moretto
Katarina Moretto
AHAlisha Holtzhausen
Alisha Holtzhausen
EUEric Ubil
Eric Ubil
Supplemental Figure 13. Macrophage signaling is affected by respective treatments.

17 June 2026
Verified
Other
Open access
PDF file
NPNestor Prieto-Dominguez
Nestor Prieto-Dominguez
PGParan Goel
Paran Goel
OOOluwagbemiga A. Ojo
Oluwagbemiga A. Ojo
KMKatarina Moretto
Katarina Moretto
AHAlisha Holtzhausen
Alisha Holtzhausen
EUEric Ubil
Eric Ubil
Supplemental Figure 2. The efficacy of chemotherapy is improved by PTP inhibition.